RxDoctor Payments Data

Renae Welke, OD

Optometrist · Rapid City, SDNPI 1487935730

Payments from drug & device makers

$1,040in general payments, 2019–2025

Across 25 payments — averaging $41.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$353
  • Apellis Pharmaceuticals, Inc.$166
  • AbbVie$147
  • Sight Sciences, Inc.$125
  • Genentech USA, Inc.$64
  • Tarsus Pharmaceuticals, Inc.$42
  • plus $144 from 7 others

What the payments were for

  • Food & beverage$84081%
  • Education$20019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,040 in reported general payments places this provider in the 65th percentile of 206 optometrist providers in South Dakota.

See all optometrist providers in South Dakota

Medicare billing

Part B allowed, 2024
$169,785
Medicare patients
747
Services billed
1,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine72$64,654
XiidraLifitegrast26$28,605
LumiganBimatoprost47$19,505
Cyclosporine25$9,636
Fluorometholone99$7,796
RocklatanNetarsudil Mesylat/Latanoprost11$6,853
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol16$4,194
Loteprednol Etabonate27$3,797
Travoprost20$3,254
Latanoprost204$1,684
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha108$1,133
Dorzolamide Hcl48$805
Brimonidine Tartrate63$764
Timolol Maleate52$677
Prednisolone Acetate19$571

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$147$84,159119 claims
Bausch & Lomb Americas Inc.Xiidra$15$28,60526 claims
Aerie Pharmaceuticals, Inc.Rocklatan$11$6,85311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 206 optometrist providers in South Dakota.

Other optometrist in Rapid City

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →